Breaking News

Pfizer-BioNTech Provide Update on COVID Vax and Omicron

Preliminary lab studies demonstrate three doses needed to neutralize the Omicron variant.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer Inc. and BioNTech’s results from an initial laboratory study demonstrate that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccines one month after receiving the booster vaccination neutralized the Omicron variant to levels that are comparable to those observed for the wild-type SARS-CoV-2 spike protein after two doses.   Sera from individuals who received two doses of the curr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters